Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avalyn PharmaAVLN -1.01%11 Cash Ratio is 9.82 as of Dec. 2025, which is 13% below its 10-year median of 11.24. GuruFocus rates AVLN with a GF Score™ of 11/100. Among 1,384 Biotechnology companies, Avalyn Pharma ranks better than 79.62% on this metric.
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Avalyn Pharma Cash Ratio Related Terms
Avalyn Pharma Cash Ratio Historical Data
* Premium members only.
The historical data trend for Avalyn Pharma's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avalyn Pharma Cash Ratio Chart
Avalyn Pharma Annual Data
Trend
Dec24
Dec25
Cash Ratio
12.65
9.82
Avalyn Pharma Semi-Annual Data
Dec24
Dec25
Cash Ratio
12.65
9.82
AVLN vs TRAX, IMTX, ARDX: Cash Ratio Comparison
For the Biotechnology subindustry, Avalyn Pharma's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avalyn Pharma Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avalyn Pharma's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Avalyn Pharma's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avalyn Pharma (AVLN) has a Cash Ratio of 9.82 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Avalyn Pharma and its competitors. This is 13% below median its historical median of 11.24. Over the past decade, Avalyn Pharma's Cash Ratio has ranged from 9.82 to 12.65. According to the industry distribution chart, Avalyn Pharma ranks #282 out of 1384 companies in the Biotechnology industry, placing it in the top 20.4%.
Is Avalyn Pharma's Cash Ratio too high?
Avalyn Pharma's current Cash Ratio of 9.82 is 13% below median its 10-year median of 11.24. Over the past 10 years, this metric has ranged from a low of 9.82 to a high of 12.65. The Biotechnology industry median Cash Ratio is 2.93. Avalyn Pharma's value of 9.82 is 235.2% above this industry median. Based on the distribution chart, Avalyn Pharma ranks #282 out of 1384 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Avalyn Pharma has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Avalyn Pharma's Cash Ratio compare to TRAX and IMTX?
According to the Biotechnology industry distribution chart, Avalyn Pharma ranks #282 out of 1384 companies for Cash Ratio. This places Avalyn Pharma in the top 20% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.93. Avalyn Pharma's value of 9.82 is 235.2% above this benchmark. Historically, Avalyn Pharma's own Cash Ratio has ranged from 9.82 to 12.65 over the past decade. While the company's 10-year median is 11.24 vs. the industry median of 2.93, Avalyn Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,384 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avalyn Pharma's current Cash Ratio of 9.82 is 235.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Avalyn Pharma and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avalyn Pharma's current Cash Ratio is 9.82, which is 13% below median its own 10-year median of 11.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalyn Pharma stock overvalued right now?
Avalyn Pharma (AVLN) has a current Cash Ratio of 9.82. The current Cash Ratio is 9.82, which is 13% below median its 10-year median of 11.24 and 235.2% above the Biotechnology industry median of 2.93. Avalyn Pharma's overall GF Score™ is 11/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Avalyn Pharma (AVLN), the current Cash Ratio is 9.82 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
11GF Score
Get the complete analysis for AVLN
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVLN has been successfully added to your 
